Market overview
The global AI-accelerated nonclinical drug testing market is worth USD 1.2 bn in 2026 and is forecast to reach USD 4.4 bn by 2036, growing at a 14.0% CAGR. United States is the largest country market and In-silico ADMET and toxicity prediction is the largest by service segment.
| Scope | In-silico and AI-guided services and software used before human trials: ADMET and toxicity prediction, PBPK and QSP modelling, AI-guided in-vitro screening and digital pathology, sold to pharma, biotech and contract research firms. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 1.1 bn |
| Value 2026 | USD 1.2 bn |
| Value 2036 | USD 4.4 bn |
| CAGR 2026-2036 | 14.0% |
| Volume 2026 | 17.5 thousand projects |
| Volume 2036 | 58.7 thousand projects |
| Average price 2026 | USD 68,420 per project |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
AI-Accelerated Nonclinical Drug Testing market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 1.2 bn |
| 2027 | USD 1.4 bn |
| 2028 | USD 1.6 bn |
| 2029 | USD 1.8 bn |
| 2030 | USD 2.0 bn |
| 2031 | USD 2.3 bn |
| 2032 | USD 2.6 bn |
| 2033 | USD 3.0 bn |
| 2034 | USD 3.4 bn |
| 2035 | USD 3.9 bn |
| 2036 | USD 4.4 bn |
AI-Accelerated Nonclinical Drug Testing market segmentation
By service
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| In-silico ADMET and toxicity prediction | 34.0% | 37.3% | USD 407 mn | 15.1% |
| PBPK and QSP modelling | 26.0% | 21.9% | USD 311 mn | 12.1% |
| AI-guided in-vitro screening | 22.0% | 24.2% | USD 263 mn | 15.1% |
| Digital pathology and image analysis | 18.0% | 16.6% | USD 215 mn | 13.1% |
By end user
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmaceutical companies | 56.0% | 50.3% | USD 670 mn | 12.8% |
| Biotechnology companies | 30.0% | 36.6% | USD 359 mn | 16.3% |
| Contract research and academia | 14.0% | 13.1% | USD 168 mn | 13.3% |
By therapeutic area
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 34.0% | 35.0% | USD 407 mn | 14.3% |
| Neurology | 18.0% | 19.0% | USD 215 mn | 14.6% |
| Cardiometabolic | 16.0% | 16.0% | USD 192 mn | 14.0% |
| Infectious disease | 12.0% | 10.0% | USD 144 mn | 11.9% |
| Immunology and rare disease | 20.0% | 20.0% | USD 239 mn | 14.0% |
By delivery model
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Software platform licence | 44.0% | 45.0% | USD 527 mn | 14.3% |
| Contract service | 42.0% | 40.0% | USD 503 mn | 13.4% |
| Hybrid platform and service | 14.0% | 15.0% | USD 168 mn | 14.8% |
By drug modality
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Small molecules | 56.0% | 51.0% | USD 670 mn | 12.9% |
| Biologics | 30.0% | 32.0% | USD 359 mn | 14.7% |
| Cell and gene therapies | 14.0% | 17.0% | USD 168 mn | 16.2% |
Top 25 countries for AI-accelerated nonclinical drug testing by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 90.0% of 2026 revenue and the 25 countries below together hold 97.9%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 551 mn | 46.0% | USD 2.0 bn | 14.0% |
| 2 | United Kingdom | USD 96 mn | 8.0% | USD 342 mn | 13.6% |
| 3 | China | USD 84 mn | 7.0% | USD 368 mn | 16.0% |
| 4 | Germany | USD 72 mn | 6.0% | USD 244 mn | 13.0% |
| 5 | Switzerland | USD 60 mn | 5.0% | USD 213 mn | 13.5% |
| 6 | Japan | USD 60 mn | 5.0% | USD 195 mn | 12.6% |
| 7 | France | USD 48 mn | 4.0% | USD 164 mn | 13.1% |
| 8 | Canada | USD 36 mn | 3.0% | USD 129 mn | 13.6% |
| 9 | India | USD 36 mn | 3.0% | USD 173 mn | 17.0% |
| 10 | Netherlands | USD 36 mn | 3.0% | USD 129 mn | 13.6% |
| 11 | Spain | USD 8.6 mn | 0.7% | USD 31 mn | 13.5% |
| 12 | Italy | USD 8.6 mn | 0.7% | USD 31 mn | 13.5% |
| 13 | South Korea | USD 8.6 mn | 0.7% | USD 34 mn | 14.8% |
| 14 | Belgium | USD 7.8 mn | 0.7% | USD 28 mn | 13.5% |
| 15 | Denmark | USD 6.9 mn | 0.6% | USD 24 mn | 13.4% |
| 16 | Sweden | USD 6.9 mn | 0.6% | USD 24 mn | 13.4% |
| 17 | Australia | USD 6.9 mn | 0.6% | USD 24 mn | 13.4% |
| 18 | Israel | USD 6.1 mn | 0.5% | USD 24 mn | 14.7% |
| 19 | Singapore | USD 6.1 mn | 0.5% | USD 24 mn | 14.7% |
| 20 | Ireland | USD 5.2 mn | 0.4% | USD 18 mn | 13.5% |
| 21 | Austria | USD 5.2 mn | 0.4% | USD 18 mn | 13.5% |
| 22 | Taiwan | USD 5.2 mn | 0.4% | USD 20 mn | 14.8% |
| 23 | Brazil | USD 4.3 mn | 0.4% | USD 19 mn | 16.0% |
| 24 | Poland | USD 4.3 mn | 0.4% | USD 17 mn | 14.9% |
| 25 | Finland | USD 4.3 mn | 0.4% | USD 16 mn | 13.7% |
| Rest of world | USD 25 mn | 2.1% | USD 87 mn | 13.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Certara
- Schrodinger
- Simulations Plus
- Charles River Laboratories
- Evotec
- WuXi AppTec
- Dassault Systèmes
Group 2: Regional and specialist players
- Optibrium
- Instem
- Insilico Medicine
- Lhasa Limited
- Genedata
- XtalPi
- Recursion Pharmaceuticals
- Rosa & Co
- Pharmaron
- BenevolentAI
Group 3: Emerging and niche players
- VeriSIM Life
- Iktos
- Aqemia
- ProtoQSAR
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the AI-accelerated nonclinical drug testing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 14.0% is calculated from the resulting values.
The market is divided by service, by end user, by therapeutic area, by delivery model, by drug modality. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the AI-accelerated nonclinical drug testing market?
The global AI-accelerated nonclinical drug testing market is estimated at USD 1.1 bn in 2025 and USD 1.2 bn in 2026.
How fast will the AI-accelerated nonclinical drug testing market grow?
It is forecast to reach USD 4.4 bn by 2036, a compound annual growth rate of 14.0% from 2026, an increase of USD 3.2 bn.
Which country is the largest market for AI-accelerated nonclinical drug testing?
United States is the largest market by revenue at USD 551 mn in 2026, 46.0% of the global total. The three largest countries together hold 61.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 17.0% a year from 2026 to 2036.
Which AI-accelerated nonclinical drug testing segment is largest?
In the by service split, In-silico ADMET and toxicity prediction is the largest segment with 34.0% of 2026 revenue.
Who are the leading AI-accelerated nonclinical drug testing companies?
Global leaders include Certara, Schrodinger, Simulations Plus, Charles River Laboratories.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Manufacturing on Demand for MedicalUSD 1.2 bn · 10.0% CAGR
- Tablet PressUSD 1.2 bn · 5.5% CAGR
- Advanced Implantable Electrode NeurotechnologyUSD 1.2 bn · 7.8% CAGR
- Microwave Ablation DevicesUSD 1.2 bn · 9.5% CAGR
- Robotic Rehab ToolsUSD 1.2 bn · 12.0% CAGR
- Catheter-Based Pulmonary Embolism ThrombectomyUSD 1.1 bn · 12.0% CAGR
- Wearable InjectorUSD 1.1 bn · 13.0% CAGR
- Medical PendantUSD 1.3 bn · 6.0% CAGR
← AI enhanced Mammography Screening AI-Assisted Clinical Trial Protocol Design →